Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
6
×
boston blog main
6
×
ipo
6
×
life sciences
national blog main
national top stories
new york blog main
san diego blog main
6
×
san diego top stories
san francisco blog main
vc
6
×
boston top stories
new york top stories
san francisco top stories
venture capital
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
national
raleigh-durham blog main
raleigh-durham top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
biogen
cancer
celgene
deals
drug development
fda
gene editing
gene therapy
novartis
startups
What
bio
roundup
ipo
new
medicines
activity
advance
aiming
allogene
ambys
approvals
becker
big
billions
biogen
biology
biopharma
biotech
cancer
car
celgene
clamped
colleagues
company
control
covid
crispr
cytokine
deadly
deal
debuted
delays
developing
diseases
diversity
dollars
drugs
eaton
economic
enhanced
Language
unset
Current search:
ipo
×
vc
×
" boston blog main "
×
" san diego blog main "
×
biotech
×
@xconomy.com
4 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
4 years ago
Bio Roundup: Michael Becker, Suzanne Eaton, Gene Therapy Moves & More
@xconomy.com
5 years ago
Bio Roundup: $74B for Celgene, Two CAR-T Tales, Ready for SF & More
@xconomy.com
5 years ago
Synthorx Files for IPO to Advance Enhanced Cytokine Drugs
@xconomy.com
5 years ago
Bio Roundup: BIO Diversity, Allogene IPO, CRISPR In Utero & More
@xconomy.com
5 years ago
With Big Takeda Deal at Launch, Can Ambys Keep Control of Its Future?